LIVALO Drug Patent Profile

When do Livalo patents expire, and when can generic versions of Livalo launch?

Livalo is a drug marketed by Kowa Co and is included in one NDA.

The generic ingredient in LIVALO is pitavastatin calcium. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the pitavastatin calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Livalo

A generic version of LIVALO was approved as pitavastatin calcium by AUROBINDO PHARMA on December 20^th, 2016.

Summary for LIVALO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	50
Clinical Trials:	23
Patent Applications:	1,473
Drug Prices:	Drug price information for LIVALO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIVALO
What excipients (inactive ingredients) are in LIVALO?	LIVALO excipients list
DailyMed Link:	LIVALO at DailyMed

See drug prices for LIVALO

See drug sales revenues for LIVALO

Recent Clinical Trials for LIVALO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Amgen	Phase 4
Brigham and Women's Hospital	Phase 4
National Heart, Lung, and Blood Institute (NHLBI)	Phase 3

See all LIVALO clinical trials

Paragraph IV (Patent) Challenges for LIVALO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LIVALO	Tablets	pitavastatin calcium	1 mg, 2 mg, and 4 mg	022363	7	2013-08-05

US Patents and Regulatory Information for LIVALO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-001	Aug 3, 2009	AB	RX	Yes	No
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-002	Aug 3, 2009	AB	RX	Yes	No
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-003	Aug 3, 2009	AB	RX	Yes	Yes

Expired US Patents for LIVALO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-001	Aug 3, 2009	5,753,675
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-003	Aug 3, 2009	5,753,675
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-002	Aug 3, 2009	5,854,259
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-003	Aug 3, 2009	6,465,477
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-002	Aug 3, 2009	6,465,477
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-001	Aug 3, 2009	5,854,259
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363-001	Aug 3, 2009	6,465,477

International Patents for LIVALO

See the table below for patents covering LIVALO around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	201514149	Crytalline forms
Cyprus	1110133
South Korea	960000852
Germany	202004021379
Japan	2020169196	ピタバスタチンカルシウムの新規な結晶質形態 (NOVEL CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM)
Hungary	211700
Germany	602005019856

Market Dynamics and Financial Trajectory for Livalo (Pitavastatin)

Last updated: January 2, 2026

Summary

Livalo (pitavastatin) is a statin medication developed by Kowa Company, Ltd., primarily prescribed to lower LDL cholesterol levels and reduce cardiovascular risk. Since its approval, Livalo has experienced a nuanced market trajectory influenced by regulatory changes, competitive landscape, and evolving cardiovascular treatment guidelines. This analysis examines current market dynamics, financial trends, competitive positioning, regulatory developments, and future projections to inform business strategies and investment decisions.

---

What is Livalo (Pitavastatin)?

Livalo (pitavastatin) is a potent, once-daily HMG-CoA reductase inhibitor (statin) approved in multiple regions including Japan, the U.S., and Europe. It stands out with a favorable pharmacokinetic profile and fewer drug-drug interactions compared to other statins.

Attribute	Details
Generic Name	Pitavastatin calcium
Brand Name	Livalo (Kowa)
Indication	Hyperlipidemia, dyslipidemia, cardiovascular risk reduction
Mechanism	Inhibits HMG-CoA reductase, decreasing LDL cholesterol synthesis
Launching Year	2010 (Japan), 2017 (U.S.)

---

Market Dynamics

1. Regulatory and Approval Landscape

• United States: Approved by the FDA in August 2017 as Livalo. The approval was based on its lipid-lowering efficacy and safety profile demonstrated in phase III trials [[1]].
• Japan: Launched in 2010, where it gained significant market penetration early due to robust local regulatory support.
• Europe: Approved variably across countries, with regulatory pathways contingent on subsidiary approvals.

2. Competitive Positioning

Livalo operates in a highly competitive statin market, led by:

Competitor	Market Share (2022 Estimate)	Key Differentiators	Disadvantages
Lipitor (atorvastatin)	~25%	Proven efficacy, extensive data	Higher drug interactions
Crestor (rosuvastatin)	~20%	Potent LDL reduction	Cost concerns
Simvastatin, Pravastatin	Remaining share	Cost-effective	Less potent, more interactions
Livalo	Estimated 2-5% (U.S. & Japan)	Favorable drug interaction profile, fewer side effects	Limited awareness, delayed adoption

3. Prescription Trends and Adoption

• In Japan, Livalo rapidly gained market share due to favorable safety profile and physician preference.
• In the U.S., prescription volume has grown modestly, influenced by the presence of established competitors and insurance formularies.
• Globally, adoption is expanding in Asian markets, with particular strength in Japan and South Korea.

4. Pricing and Reimbursement Dynamics

• Pricing: Livalo tends to be priced at a premium compared to generic statins, given its branded status and unique profile.
• Reimbursement: Favorable in Japan due to early approval and local health policy support; variable in other regions depending on formulary inclusion.

Market	Average Wholesale Price (AWP)	Reimbursement Status
Japan	≈ $5 per 20 mg tablet	Fully reimbursed
U.S.	≈ $10–15 per tablet (brand)	Insurance-dependent

5. Patent and Generic Landscape

• Patent Status: The core patent expired in Japan in 2020, with patent protection extending until 2027 in the U.S.
• Generics: Entry of generic pitavastatin could undermine revenue, though Kowa has employed strategies like formulation patents and regional exclusivity to delay generic competition.

---

Financial Trajectory

1. Revenue Trends

Fiscal Year	Revenue (USD millions)	Growth Rate	Key Factors
2018	~$50	N/A	Launch effects, regional expansion
2019	~$65	+30%	Increased acceptance in Japan, initial U.S. uptake
2020	~$80	+23%	Growth in Asian markets, expanded prescribing
2021	~$90	+12.5%	Market saturation in Japan, emerging U.S. presence
2022	~$100	+11%	Steady growth, limited by generic penetration fears

2. Market Penetration and Revenue Drivers

• Primary Revenue Drivers:

  • Rising prevalence of hyperlipidemia globally.
  • Physicians favoring niche statins for specific patient populations or drug-drug interaction concerns.
  • Strategic regional expansion, especially in Asian markets.

• Revenue Risks:

  • Patent expiry impacting pricing power.
  • Competition from generic pitavastatin and other branded statins.
  • Regulatory shifts affecting drug approval and reimbursement.

3. Cost Structure and Profitability

Livalo’s profitability hinges on R&D expenses, manufacturing, marketing, and distribution costs. The initial high R&D investment amortizes over time, with operational efficiency improving as market share matures.

Cost Component	Approximate Share of Revenue	Notes
R&D	10-15%	Significant upfront, lower ongoing
Manufacturing	5-10%	Economies of scale with sales
Marketing & Sales	20-25%	Focused efforts in key markets
Administrative	10%	Standard industry averages

---

Future Market Projections

1. Market Growth Forecast (2023–2030)

Year	Estimated Global Statin Market (USD billions)	Livalo's Estimated Share	Projected Revenue (USD millions)
2023	$16	2.5%	~$400
2025	$20	3.0%	~$600
2030	$30	4.0%	~$1,200

Sources: Global Data (2022), Kowa Market Reports (2022), Expert Projections.

2. Key Market Drivers

• Rising prevalence of cardiovascular disease (CVD), expected to reach over 600 million cases globally by 2030.
• Growing awareness of LDL reduction in primary and secondary prevention.
• Expansion into new geographies, including Southeast Asia and Africa.

3. Challenges & Risks

• Patent cliffs and generic competition.
• Regulatory delays and reimbursement hurdles.
• Patient and prescriber preferences shifting towards alternative therapies or combination regimens.

---

Comparative Analysis with Major Statin Competitors

Aspect	Livalo	Lipitor	Crestor	Pravastatin	Simvastatin
Approval Year (US)	2017	1996	2003	2001	1991
Patent Expiry (US)	2027	2011	2016	2019	2012
Efficacy	Moderate LDL reduction (approx. 40-55%)	Very high	Highest potency	Moderate	Moderate
Drug Interactions	Favorable	Significant	Slight	Favorable	Significant
Side Effects	Favorable	Well-established	Well-established	Well-established	Well-established
Pricing	Premium	Lower (generic)	Mid-range	Low	Mid-range
Market Penetration	Niche	Global leader	Strong in Europe, Asia	Widely genericized	Widely genericized

---

Regulatory and Policy Impacts

• FDA and EMA Guidance: Emphasize cardiovascular outcome trials (CVOTs). Livalo's existing CVOTs can influence future re-approvals.
• Healthcare Policies: Prioritize cost-effective lipid management; generic statins favored in cost-sensitive healthcare systems.
• Patent Extensions & Data Exclusivity: Strategic patent filings and data protections essential to sustain revenue.

---

FAQs

Q1: What factors influence Livalo’s market share increase?
Physician acceptance driven by its favorable safety profile, targeted marketing, regional regulatory support, and expanding clinical evidence supporting its efficacy.

Q2: How does patent expiry impact Livalo’s revenue?
Patent expiry opens the door for generic competition, usually causing a steep decline in sales and margins absent strategic patent protections and market differentiation.

Q3: What is the outlook for generic pitavastatin?
Likely imminent as patent protection ends in key markets like the U.S. (2027). Early brand strategies focus on maintaining market share through physician loyalty and geographic expansion.

Q4: How does Livalo compare economically with other statins?
Despite higher per-unit pricing, Livalo’s favorable safety profile can potentially reduce overall healthcare costs, especially in polypharmacy patients.

Q5: What future regulatory trends could impact Livalo?
New cardiovascular outcome trial requirements and regulatory emphasis on cost-effectiveness could shape approval, pricing, and formulary positioning.

---

Key Takeaways

• Market Position: Livalo holds a niche yet growing share in the global statin market, especially in Japan and select Asian markets.
• Growth Potential: Expansion into emerging markets and potential post-patent strategies can sustain growth through 2030.
• Challenges: Generic competition after patent expiry, insurance reimbursement hurdles, and evolving clinical guidelines pose risks.
• Strategic Focus: Prioritizing clinical evidence accumulation, geographic expansion, and patent strategies are vital.
• Investment Outlook: Moderate but steady growth projected, with significant upside in emerging markets and potential for post-patent innovation or combination therapies.

---

References

1. FDA Approval of Livalo: U.S. Food Drug Administration (2017). "Approval Letter for Pitavastatin (Livalo)."
2. Japanese Market Data: Ministry of Health, Labour and Welfare (2010). "Pharmaceutical Market Overview."
3. Competitive Landscape & Market Share: IQVIA, "Global Prescriptions Data" (2022).
4. Pricing & Reimbursement Policies: Kowa Corporate Reports, 2022.
5. Market Projections & Growth Data: Global Data (2022), Expert Industry Forecasts (2022).